The Global Health Innovative Technology Fund (GHIT Fund) is a public-private partnership that leverages Japanese innovation, investment, and leadership to advance the development of new health technologies such as drugs, vaccines and diagnostics, for the developing world. It is the first fund to involve a consortium of pharmaceutical companies (Astellas Pharma Inc., Daiichi Sankyo & Co. Ltd., Eisai, Shionogi & Co. Ltd., and Takeda Pharmaceutical Co. Ltd.), government (the Japanese Ministries of Foreign Affairs and Health, Labour and Welfare and the United Nations Development Programme), and civil society (the Bill & Melinda Gates Foundation) working together to support R&D for neglected diseases.

Vision
The GHIT Fund’s vision is one in which the crushing burden of infectious disease no longer prevents billions of people in the developing world from seeking the level of prosperity and longevity now common in the industrialized world.

Mission
The mission of the GHIT Fund is to facilitate international partnerships that enable Japanese technology, innovations, and insights to play a more direct role in reducing disparities in health between the rich and the poor of the world.